



TRANSLATE!

May 22–23, 2014
Berlin, Germany

Translate! 2014

Open Forum for Translational Research

Joining Forces for
Translational Research in Life Sciences

Berlin, Germany
May 22nd - 23rd, 2014



Berlin-Brandenburg Center
for Regenerative Therapies **BCRT**



Berlin-Brandenburg
School for Regenerative Therapies



**BERLIN
INSTITUTE
OF HEALTH**
Charité & Max Delbrück Center



Science
Translational
Medicine
AAAS

SPONSORED BY THE



CHARITÉ
UNIVERSITÄTSMEDIZIN BERLIN



**HELMHOLTZ
ASSOCIATION**



Federal Ministry
of Education
and Research



DFG



LAND
BRANDENBURG



berlin Berlin

Doing the right thing while doing things right

Basic discoveries in all areas of biomedicine are accelerating, yet the development of corresponding new therapies and diagnostics – the translation of basic research into concrete clinical outcomes – is lagging behind. So what exactly is hindering swift translation of research findings into tangible therapeutic results?

Peter Drucker once said, “Management is doing things right; leadership is doing the right things.” In translational research, doing the right thing means doing what is best for our community, for ensuring patient health. However, for the translational process to be successful, things should also be done right by meeting three criteria: technological feasibility, economic viability, and an unmet need.

It is extremely challenging to meet all of these requirements. Thus, it is crucial that we devise an effective strategy for conducting meaningful translational research - a consensus that can be applied across all disciplines, in all areas of medicine. In order to address this challenge, the Berlin-Brandenburg Center for Regenerative Therapies and its graduate school, the Berlin-Brandenburg School for Regenerative Therapies, intend to establish at the Berlin Institute of Health (BIH) a shared platform to allow all interest groups to create a common understanding of what it takes to translate research in life sciences. We will discuss the tools required for success in translation, enabling a targeted education, and facilitation of future translational scientists. **Translate! 2014**, the kick-off event of the “Open Forum for Translational Research” in collaboration with the journal *Science Translational Medicine* will provide such a platform. This Open Forum will address such questions as:

- How can different interest groups join forces to spur translational research?
- Which factors support a successful translational researcher?
- How do stakeholders in academia, industry, and government enable more scientists to conduct patient-oriented research with the long-term goal of improving public health?

Translate! 2014 will bring together thought leaders from basic and translational science, industry, funding bodies, and regulatory agencies to discuss the future of translational research worldwide.

We hope you can join us in Berlin.

Prof. Dr. Georg N. Duda
BCRT / BSRT

Megan Frisk, PhD
Science Translational Medicine

Prof. Dr. Ernst Th. Rietschel
BIH



Program

Thursday, May 22nd 2014

Time	Program	Speaker
2.00pm	Registration and Reception	
2.15pm	Welcome	<p>Karl Max Einhaeupl Chairman of the Executive Board, <i>Charité Universitaetsmedizin Berlin,</i> Berlin, Germany</p> <p>Ernst Th. Rietschel Chairman of the Directorate, <i>Berlin Institute of Health,</i> Berlin, Germany</p>
2.30pm	Opening Statements	<p>Georg Schuette State Secretary, <i>Federal Ministry of Education and Research,</i> Berlin, Germany</p> <p>Leena Bruckner-Tuderman Vice President of the <i>Deutsche Forschungsgemeinschaft,</i> Freiburg, Germany</p>
3.00pm	Purpose of Symposium	<p>Georg N. Duda Vice-Director of the BCRT Director <i>Julius Wolff Institute,</i> <i>Charité Universitaetsmedizin Berlin,</i> Berlin, Germany</p> <p>Megan Frisk Associate Editor at <i>Science Translational Medicine,</i> Washington, D.C., USA</p>

3.15pm **Translational Research at Helmholtz**

Guenther Wess
Vice President of
Helmholtz Association
Research Field Health,
Munich, Germany

3.30pm **“Travelogues”**
Successful Journeys through the Translational Research
Process

Carl H. June
Perelman School of Medicine,
University of Pennsylvania,
Pennsylvania, USA

David J. Mooney
Core Faculty Member,
Wyss Institute for Biologically Inspired
Engineering at Harvard University,
Boston, USA

Werner Seeger
Director of the *Medical Clinic/Executive*
Director of the *Center of Internal*
Medicine of the University Giessen,
Giessen, Germany

4.30pm **Coffee Break**

5.00pm **Panel Discussion**
Collecting the Nuggets: What Are Key Factors
Supporting Translational Researchers?

Moderator:
David W. Grainger
University of Utah,
Salt Lake City, USA

6.30pm **Opening Dinner and Fireside Chats**

A Cure for a Rare Disease in Three Days

Alex Veldman
Faculty of Medicine, Nursing and Health
Sciences, Monash University,
Melbourne, Australia

New Opportunities for Translation: Crossing the
Rubicon between Academia and Commerce

Christoph Huber
Prof. Emeritus, Former Chairman Dpt.
Hematology-Oncology at the Mainz
University Medical Center,
Mainz, Germany; Chairman CIMT;
Board Member CI3-Cluster; TRON

Major Players in Global R+D: Old Fears, New Hope

Elliott Gruskin
Worldwide President Biomaterials
DePuy Synthes,
Pennsylvania, USA

Friday, May 23rd 2014

Time	Program	Speaker
9.00am	Welcome & Warm Up	Megan Frisk, David Grainger
9.15am	Setting the Course: Different Entry Pathways to the Translational Research Process	
	Basic Science-Driven Translational Research: Reducing Waste and Improving Value of Translational Medicine: What Went Wrong in Basic Stroke Research?	Ulrich Dirnagl <i>Department of Experimental Neurology, Charité Universitaetsmedizin Berlin, Berlin, Germany</i>
	Technology-Driven Translational Research: Does Material Science ever Meet a Medical Need?	Molly Stevens <i>Faculty of Engineering, Department of Materials, Imperial College, London, UK</i>
	Economy-Driven Translational Research: Why does <i>Big Pharma</i> Allocate Resources to Academia?	Robert Urban <i>Head of Johnson & Johnson Innovation Center, Boston, USA</i>
	Medical Need-Driven Translational Research: Measuring Success in Translation – Is it Economic? Commercial Entry? High Impact Publications only? Numbers of Patients Treated? How Should Agencies Who Fund this Work View Translational Success? How Much Time Is Tolerated for Ideas to Move from Concept to Clinic?	Andrew Carr <i>Nuffield Professor of Orthopaedics/ Head of the Nuffield Department of Orthopaedics, Botnar Institute of Musculoskeletal Sciences, University of Oxford, Oxford, UK</i>
11.00am	Coffee Break	
11.30am	Panel Discussion Joining Forces: Most Effective Ways to Initiate Translational Research	Moderation: Megan Frisk
1.00 pm	Lunch	
2.30pm	Organizational Concepts for Translational Research	
	Translational Research in MedTech – What are the Challenges for Academic Research?	Stephen Gottschalk <i>Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA</i>
	The Innovative Medicines Initiative (IMI) – Public-Private Partnership Boosting Innovation in Healthcare	Michel Goldman <i>Executive Director, Innovative Medicines Initiative (IMI), Bruxelles, Belgium</i>
	Refined Internal Translational Strategy in	Hans-Dieter Volk

Regenerative Medicine and beyond

Director of the BCRT/Director of the
Medical Immunology at the Charité
Universitätsmedizin Berlin,
Berlin, Germany

4.30pm	Break	
5.00-5.30pm	Summary of the Symposium & Closing Remarks	Guenther Wess Megan Frisk Georg N. Duda



TRANSLATE!

May 22–23, 2014
Berlin, Germany

REGISTRATION

Click here to register:

[HTTP://TRANSLATE-EVENT.CHARITE.DE/?PAGE_ID=21](http://translate-event.charite.de/?page_id=21)

VENUE

Best Western Premier Hotel Moa Berlin

Stephanstrasse 41
10559 Berlin / Germany
[HTTP://WWW.HOTEL-MOA-BERLIN.DE/](http://www.hotel-moa-berlin.de/)

ACCOMMODATION

Click here to get to the hotel allotments:

- [HTTP://EN.INTERCITYHOTEL.COM/BERLIN/INTERCITYHOTEL-BERLIN-HAUPTBAHNHOF](http://en.intercityhotel.com/Berlin/intercityhotel-berlin-hauptbahnhof)
- [HTTP://WWW.NOVOTEL.COM/GB/HOTEL-3649-NOVOTEL-BERLIN-AM-TIERGARTEN/INDEX.SHTML](http://www.novotel.com/gb/hotel-3649-novotel-berlin-am-tiergarten/index.shtml)
- [HTTP://WWW.HOTEL-MOA-BERLIN.DE/](http://www.hotel-moa-berlin.de/)

(Reference: *Translate! 2014*)

CONTACT

Mrs. Bettina Mueller
RRC-Congress GmbH
Französische Straße 14
10117 Berlin / Germany
Fon: +49 (0) 30 72 39 33 – 0
Fax: +49 (0) 30 72 39 33 – 22
E-Mail: info@rrc-congress.de



Partners

BERLIN-BRANDENBURG CENTER FOR REGENERATIVE MEDICINE



Berlin-Brandenburg Center
for Regenerative Therapies **BCRT**

The *BCRT* was established as an interdisciplinary translational center with the goal of enhancing endogenous regeneration by cells, biomaterials, and factors which can be used to develop and implement innovative therapies and products. The primary focus of the *BCRT* is on diseases of the immune system, the musculoskeletal system and the cardiovascular system for which currently only unsatisfactory treatment options are available. At the *BCRT* clinicians and researchers are working closely together on the medicine of the future: Targeted, personalized medicine that depends on the early recognition of patients' individual healing potential.

SCIENCE TRANSLATIONAL MEDICINE



The mission of *Science Translational Medicine* is to promote human health by providing a forum for communication and cross-fertilization among basic, translational, and clinical researchers and trainees. *Science Translational Medicine* publishes original, peer-reviewed research in all areas of science, engineering, and medicine that advances clinical medicine toward the goal of improving patients' lives.

BERLIN INSTITUTE OF HEALTH



Charité & Max Delbrück Center

The *Berlin Institute of Health (BIH)* is a cooperation of the **Charité – Universitätsmedizin Berlin** with the Max Delbrück Center for Molecular Medicine. Currently, this cooperation is based on a treaty between the two parties. In 2015, the *BIH* will be institutionalized as a corporation under public law in which the two parties MDC and Charité will remain as independent corporations. Research within the framework of the *BIH* focuses on translational systems medicine.

HELMHOLTZ-ASSOCIATION



The *Helmholtz Association* is Germany's largest scientific research organisation. A total of 36,000 staff work in its 18 scientific-technical and biological-medical research centres. The Association's annual budget amounts to more than €3.8 billion. The Federal and Laender authorities share around 70% of the total budget in a ratio of 90:10. The remaining 30% of the budget is acquired by the *Helmholtz Centres* in the form of contract funding.

The *Helmholtz Association* performs cutting-edge research which contributes substantially to solving the grand challenges of science, society and industry. Scientists at *Helmholtz* concentrate on researching the highly-complex systems which determine human life and the environment. For example, ensuring that society remains mobile and has a reliable energy supply that future generations find an intact environment or that treatments are found for previously incurable diseases. The activities of the *Helmholtz Association* focus on securing the foundations of human life long-term and on creating the technological basis for a competitive economy. The potential with which the Association achieves these goals is made up of the outstanding scientists working at the research centres, a high-performance infrastructure and modern research management.

DEUTSCHE FORSCHUNGSGEMEINSCHAFT



The *DFG* is the self-governing organisation for science and research in Germany. It serves all branches of science and the humanities. In organisational terms, the *DFG* is an association under private law. Its membership consists of German research universities, non-university research institutions, scientific associations and the Academies of Science and the Humanities.

The *DFG* receives the large majority of its funds from the states and the Federal Government, which are represented in all Grants Committees. At the same time, the voting system and procedural regulations guarantee science-driven decisions.

BERLIN-BRANDENBURG SCHOOL FOR REGENERATIVE MEDICINE



**Berlin-Brandenburg
School for Regenerative Therapies**

The *Berlin-Brandenburg School for Regenerative Therapies (BSRT, graduate school 203 of the German Excellence Initiative)* offers interdisciplinary training and research opportunities in the field of Regenerative Medicine for out-standing doctoral and postdoctoral researchers with a background in the biological, engineering or clinical disciplines. Young scientists at the *BSRT* benefit from our worldwide unique approach to foster collaborative science (BioThinking) and work within a strong and intellectually stimulating network of institutions and scientists.

CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN



The *Charité* is one of the largest university hospitals in Europe. Here, 3700 doctors and scientists heal, do research and teach at the top international level. More than half of the German Nobel Prize winners in medicine and physiology come from the *Charité*, among them Emil von Behring, Robert Koch and Paul Ehrlich. The *Charité* also has an international reputation for excellence in training. It extends over four campuses with more than 100 clinics and institutes bundled under 17 CharitéCenters. With 13,200 employees, the *Charité* generates about 1.3 billion euros in sales per year and is one of the largest employers in Berlin. In 2010, the *Charité* could look back and joyously celebrated its 300-year anniversary.

SPONSORED BY THE



The *BMBF's* funding of science and research must be judged according to the benefits which the use of public funding holds for society, particularly in the long term. Such an assessment must be oriented towards the future and must take various factors into account.

The first of these is providing for the future: The protection of the environment and climate change, safeguarding energy supplies, but also demographic development is all processes which take several decades. Although we cannot forecast these processes precisely today, scientifically founded predictions of developments make it necessary to fund research into countermeasures.

A second factor is securing the basis for our prosperity and social cohesion. Many research results have considerable economic significance. They form the basis for the international competitiveness of highly developed technological nations. Here it is, of course, important that the results of research enter products and services and that research also reaches the people whom it can help - particularly in fields such as health research.

In order to remain in the lead internationally, it is decisive to identify the future direction of research as early as possible and to support work in this area. The third factor is the rather abstract progress in science and research in general. Findings and discoveries in research can often not be determined in advance - this is the reason for their scientific charm and societal importance. This research has its origins in scientific questions, answers to which also require support.

Strategy processes in education and research are thus based on two fundamental questions: Where do we stand and in what direction do future developments point? Working on the basis of the results of analyses and scenarios, we can develop a dialogue with science and societal groups on central areas and key measures needed to achieve the goals of education and research policy.